Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide.

NLM AIDSLINE
Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide.
Weber KT; Hammache D; Fantini J; Ganem B; Department of Chemistry and
December 30, 2000
Unique Identifier : AIDSLINE MED/20300190

HIV-1 has been shown to infect CD4 negative cells by the binding of HIV gp120 to the glycolipid galactosylceramide (1) (GalCer). Several analogues of 1 were prepared to investigate the specific orientation of 1 in the membrane bilayer that is involved in gp120 binding. Interestingly, N-stearyl-1-deoxynojirimycin (8) displayed potent and specific affinity for gp120 equal to that of 1, a finding that may shed light on the antiviral activity of N-butyl-1-deoxynojirimycin.

JOURNAL ARTICLE Anti-HIV Agents/CHEMICAL SYNTHESIS/METABOLISM/PHARMACOLOGY Galactosylceramides/*METABOLISM Glycolipids/*CHEMICAL SYNTHESIS/*METABOLISM/PHARMACOLOGY HIV Envelope Protein gp120/*METABOLISM Lipid Bilayers

www.aegis.org